|
|
 |
|
Viewing report
|
|
|
|
Cephalon Inc.: PharmaVitae Profile
Datamonitor, Dec 2010, Pages: 88
Introduction
This analysis examines the historical and forecast performance for Cephalon in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Cephalon's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
- Strategic insight into the prospects for Cephalon over the next six years.
- Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Cephalon's performance against key rivals in the prescription pharmaceutical sector
- Assess the effects of the patent expiry of Provigil on the company
- See how two products, Treanda and Amrix, will generate new growth for the company in new therapy areas.
|
|
|
|
